Inhibace

Cilazapril, the active ingredient in Inhibace, is an angiotensin-converting enzyme (ACE) inhibitor presented as an oral formulation for systemic use. It is employed to lower elevated blood pressure and to improve outcomes in patients with heart failure.

GNH USA supplies Inhibace as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels. The company ensures consistent batch integrity and supports pharmacovigilance reporting for safe patient care.

Cilazapril, an ACE inhibitor, is used to treat conditions involving the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and cardiovascular events in adults. - Heart failure: improves cardiac output and reduces symptoms such as dyspnea and edema, helping to delay disease progression. - Cardiovascular risk reduction: decreases incidence of myocardial infarction and other major adverse cardiac events in high‑risk patients.

Cilazapril may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue or general weakness. - Mild hypotension. - Elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension leading to fainting. - Acute renal impairment or failure. - Significant hyperkalemia. - Hepatic dysfunction with jaundice. - Neutropenia or other blood dyscrasias.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor key parameters.

- Monitor blood pressure: adjust therapy if target levels are not achieved. - Assess renal function: check serum creatinine and eGFR regularly. - Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Use with caution in hepatic impairment: dose may need adjustment. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Cilazapril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of severe hypotension, hyperkalemia, and renal dysfunction. - Lithium: increased lithium levels may cause toxicity. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: additive blood‑pressure lowering effect. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Rifampin: may decrease cilazapril plasma concentrations. - Other antihypertensives: monitor for excessive hypotension.